← All trials
NCT06376396
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Apr 19, 2024
- Last posted
- Apr 23, 2024
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- R-Evolution Worldwide S.r.l. Impresa SocialeLead sponsor
- Muhimbili UniversityCollaborator
- National Institute for Medical Research, TanzaniaCollaborator
- R-Evolution Worldwide S.r.l. Impresa SocialeSponsor investigator
- University of ZambiaOfficial
- Ghent UniversityCollaborator
- University of ZambiaCollaborator
- Sokoine University of AgricultureCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.